Ovarian cancer remains one of the most challenging malignancies to treat, primarily due to its often late diagnosis and the genetic complexity underlying its pathology. Among the key mechanisms that influence therapeutic response is homologous recombination deficiency, a state where cells lose the ability to accurately repair double-strand DNA breaks. This immunocompromised repair pathway renders tumors exquisitely sensitive to platinum-based chemotherapies and PARP inhibitors such as olaparib, which exploit the tumor’s inability to mend DNA damage effectively.

Despite the clinical importance of identifying HRD tumors, the landscape of HRD testing is populated by numerous assays, many of which have yet to undergo rigorous prospective validation. This gap has hampered the widespread integration of HRD testing into routine practice. Addressing this need, the HERO trial launched an ambitious effort to prospectively validate the GIScar test across multiple French oncology centers, focusing on newly diagnosed HGSOC patients undergoing first-line platinum-based chemotherapy.

The core of the HERO trial is to determine the predictive power of GIScar in identifying platinum-sensitive patients. Platinum sensitivity, in this context, is defined as the absence of disease progression within six months following the completion of first-line chemotherapy, according to the established RECIST 1.1 criteria. This endpoint offers a robust clinical correlate of therapeutic efficacy and sets the stage for personalized treatment planning based on molecular tumor profiling.

Integral to the study design is the comparative evaluation of GIScar alongside the commercially available MyChoice CDx assay developed by Myriad Genetics®. Both assays evaluate HRD status but differ in methodology and genomic targets. This head-to-head comparison aims to elucidate the concordance between the tests and the relative performance of the newly developed GIScar platform, which leverages next-generation sequencing (NGS) to detect genomic scars indicative of HRD.

The trial plans to enroll 88 patients, each subjected to both GIScar and MyChoice CDx analyses. Post molecular testing, patients will uniformly receive platinum-based chemotherapy, with or without bevacizumab, as dictated by the treating clinicians’ judgment and established guidelines. Subsequent maintenance therapy with olaparib—a PARP inhibitor—will be administered to patients demonstrating at least one positive HRD test, reflecting evolving clinical recommendations that prioritize targeted therapy for molecularly defined subgroups.

From a methodological standpoint, the GIScar assay represents a significant advancement in molecular diagnostics for ovarian cancer. Developed within an academic setting, this test is grounded in the detection of genomic instability patterns using NGS technology, aiming to provide a cost-effective and accessible alternative to proprietary commercial assays. If validated, GIScar has the potential to democratize HRD testing by facilitating broader access within public and private healthcare systems while maintaining high sensitivity and specificity.

Beyond the primary endpoint focusing on platinum sensitivity, the HERO trial incorporates critical secondary evaluations including overall survival and progression-free survival stratified by HRD status. Additionally, the study will monitor the kinetic changes in serum CA-125 levels via a kinetic elimination model (KELIM), a biomarker known to correlate with disease dynamics and treatment response in ovarian cancer. Such multifaceted analyses underscore the comprehensive nature of the trial’s design.

The implications of this study transcend the immediate context of ovarian cancer treatment. The integration of GIScar testing aligns with a larger paradigm shift in oncology that leverages genomic profiling to inform targeted therapy. This transition towards precision medicine heralds an era where treatments are increasingly tailored to the molecular underpinnings of individual tumors, maximizing efficacy and minimizing unnecessary toxicities.

Furthermore, the HERO trial exemplifies the critical role that academic and institutional research plays in complementing and challenging commercial diagnostic platforms. By advancing novel, cost-effective assays through rigorous clinical validation, the scientific community fosters competition and innovation, driving down costs and widening patient access to cutting-edge diagnostic tools.

Technical challenges inherent to HRD testing include the heterogeneity of tumor samples and the dynamic nature of genomic instability. The GIScar test employs intricate bioinformatic algorithms to quantify genomic scars, capturing a composite measure of DNA repair deficiency that extends beyond single gene mutations. This holistic view improves the sensitivity of detection, crucial for delineating true HRD-positive tumors that would benefit most from DNA repair targeting agents.

The HERO trial’s prospective nature marks a pivotal departure from retrospective analyses that have traditionally informed HRD test validation. Prospective validation offers heightened reliability by encompassing real-time clinical decision-making and outcomes, thus providing clinicians and regulatory agencies with robust evidence to endorse test use in standard care protocols.

As the trial is poised to continue follow-up for 48 months post-inclusion, the accrued data will provide longitudinal insights into the durability of treatment responses and long-term survival outcomes. These longitudinal analyses are critical in chronicling the impact of HRD-guided therapies on the natural history of ovarian cancer.

In an era where next-generation sequencing has revolutionized cancer genomics, the HERO study underscores the necessity of translating complex molecular data into clinically actionable formats. By refining the tools used to identify HRD, the study enhances oncologists’ armamentarium in the battle against ovarian cancer, promising personalized therapeutic routes with improved prognostic accuracy.

Going forward, wider adoption of validated HRD tests like GIScar could pave the way for a more nuanced understanding of tumor biology, fostering adaptive clinical trial designs that incorporate biomarker stratification. This approach not only heightens trial efficiency but accelerates the pace at which new targeted agents reach patients in need.

Ultimately, the HERO trial encapsulates the synergy between molecular innovation and clinical rigor. As the oncology field eagerly awaits the final results, the study portends a future where precision oncology is not a privilege but a standard, ensuring that ovarian cancer patients receive therapies explicitly tailored to the molecular vulnerabilities of their tumors.

The expanding repertoire of HRD assays, bolstered by studies such as HERO, is emblematic of the relentless pursuit to harness genomic information for improved patient outcomes. By grounding diagnostics in robust clinical evidence and technological innovation, the research community is charting a transformative course for cancer care.

Subject of Research: Homologous recombination deficiency (HRD) testing for therapeutic stratification in ovarian cancer.

Article Title: Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).

Article References:
Leman, R., Cherifi, F., Leheurteur, M. et al. Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).
BMC Cancer 25, 1075 (2025). https://doi.org/10.1186/s12885-025-14423-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14423-2

Dr. Ahmad’s multifaceted expertise combines clinical cardiology with molecular genetics and genomics, lending a unique perspective that is primed to propel the journal into new scientific territories. He currently serves as the founding director of the Cardiovascular Genomics Program at the University of Iowa’s Carver College of Medicine and holds associate professorships in internal medicine-cardiovascular medicine, molecular physiology and biophysics, and radiology. These overlapping roles underscore his interdisciplinary approach to unraveling the complex genetic architectures of cardiovascular diseases.

His research laboratory focuses on elucidating the genetic and genomic mechanisms underlying a spectrum of inherited cardiovascular conditions such as hypertrophic cardiomyopathy, dilated cardiomyopathy, glycogen storage cardiomyopathy, inherited arrhythmias, and pulmonary hypertension. By leveraging both basic and translational research modalities—including in vitro systems and animal models—Ahmad seeks to translate genomic insights into therapeutic avenues. One notable investigative thread in his work explores the role of the SGLT1 protein in heritable and acquired heart failure, highlighting molecular pathways with direct clinical relevance.

During his decade-long tenure as associate editor and senior associate editor of the Journal of the American Heart Association (JAHA), Dr. Ahmad helped to shape a dynamic editorial vision that elevated the journal’s scientific rigor and global reputation. Resigning from this role to focus fully on his new position, he expresses commitment to expanding Circulation: Genomic and Precision Medicine’s reach by amplifying emerging fields in cardiovascular genomics and fostering scientific innovation. His leadership aims to balance fundamental research discoveries with clinical implementation, an approach critical to bridging the gap from bench to bedside.

A hallmark of Ahmad’s editorial philosophy is the incorporation of community-engaged and equitable research frameworks. Recognizing that cardiovascular genetics is deeply intertwined with social determinants of health, he plans to spotlight studies that integrate implementation science and participatory research methodologies. These approaches are pivotal in addressing disparities and ensuring that genomic medicine advances inclusively, benefiting diverse populations and improving outcome stratifications across socioeconomic and ethnic groups.

Moreover, Dr. Ahmad envisions broadening the journal’s scope to encompass interdisciplinary collaborations that intersect with other medical specialties, health professionals, and early-career scientists. By fostering an editorial platform that invites contributions from underrepresented communities and perspectives—including patients and their families—he aims to cultivate a holistic scientific dialogue enriched by diverse voices. This strategy is designed to reflect the multifactorial nature of cardiovascular diseases, where genetics, environment, and patient experience converge.

The expansion of the editorial board is another priority under Ahmad’s stewardship, with targeted inclusion of international experts to enhance the journal’s global footprint. As cardiovascular genomic research transcends geographic boundaries, this move will facilitate cross-cultural scientific exchange and ensure that the journal remains a vanguard publication in disseminating state-of-the-art precision medicine discoveries worldwide.

Dr. Ahmad’s academic journey laid the foundation for his multidisciplinary expertise. He attained his M.D. degree from McGill University in Montreal, followed by postgraduate clinical training at McGill, Baylor College of Medicine, and Brigham and Women’s Hospital. Pursuing a Ph.D. in human genetics at Baylor, he subsequently completed a Howard Hughes Medical Institute postdoctoral fellowship in mouse genetics at Harvard Medical School, underscoring his strong background in both clinical and experimental genetics.

Involvement with the American Heart Association spans many leadership roles beyond editorial duties. Ahmad has been actively engaged in the Council on Genomic and Precision Medicine, Council on Epidemiology and Prevention, and the Committee for Scientific Sessions Programming. His service on the Hypertrophic Cardiomyopathy Science Advisory Group further exemplifies his commitment to clinically impactful research and guideline development within inherited cardiovascular disorders.

Scientifically, Ahmad has been prolific, authoring over 60 peer-reviewed articles and contributing significantly to the field’s foundational literature. Notably, he chaired the writing group for the 2019 American Heart Association Scientific Statement on establishing specialized clinical cardiovascular genetics programs, a landmark document emphasizing standards and frameworks for integrating genetic medicine into cardiology practice. His expertise also extends to educational resources, authoring the chapter on cardiovascular genetics in the American College of Cardiology’s Self-Assessment Program.

Circulation: Genomic and Precision Medicine commenced publication in 2008 and has since established itself as the leading journal dedicated to mechanistic, diagnostic, prognostic, and therapeutic innovations in cardiovascular genetics and genomics. The journal’s scope spans human studies, animal models, in vitro assays, and computational analyses, with an emphasis on translational relevance. An online-only platform publishing six issues per year, it ensures rapid dissemination of emerging science pertinent to cardiovascular biology and disease.

The journal occupies a vital niche in the portfolio of 14 American Heart Association peer-reviewed scientific journals, including flagship titles such as Circulation, Stroke, Hypertension, and the Journal of the American Heart Association. Each operates with editorial independence, governed by volunteer-led scientific publishing committees that select editors-in-chief responsible for shaping the journal vision. This model encourages open scientific discourse crucial for advancements in cardiovascular research and clinical care.

Peer review and scientific integrity remain paramount within the American Heart Association’s journals. Manuscripts undergo rigorous evaluation to ensure methodological soundness and potential clinical impact. Importantly, the Association maintains a clear separation between its administrative role and scientific content, safeguarding editorial freedom and accuracy. Funding structures prioritize diverse sources, including individual and foundation contributions, with strict policies preventing corporate influence to maintain the integrity of published science.

Under Dr. Ahmad’s leadership, Circulation: Genomic and Precision Medicine is poised to embrace a future where cardiovascular genomics is deeply integrated with precision health paradigms. His vision emphasizes collaborative engagement, diversity, patient-centered research, and global perspectives. This trajectory aligns with the broader movement in medicine towards personalized interventions shaped by genomic data, environmental context, and social determinants—ultimately transforming cardiovascular care and outcomes on a global scale.

Subject of Research: Cardiovascular genomics and precision medicine, inherited cardiovascular disorders, implementation science in genomic cardiovascular medicine.

News Publication Date: April 15, 2025

Web References:

• Circulation: Genomic and Precision Medicine Journal
• 2019 AHA Scientific Statement on Clinical Cardiovascular Genetics Programs

Keywords: Cardiovascular genomics, precision medicine, genetic cardiomyopathies, inherited cardiovascular diseases, SGLT1 protein, cardiovascular genetics programs, implementation science, equitable health, translational research, clinical cardiology, peer-reviewed scientific journals, American Heart Association

The individuals selected for the 2025 ACMG Foundation Next Generation Fellowship embody the innovative spirit and dedication essential for advancing the field of genomics. As expressed by Nancy J. Mendelsohn, MD, FACMG, the president of the ACMG Foundation, these outstanding clinician-scientists represent the pinnacle of talent in the evolving landscape of genetics and genomics. Their groundbreaking work is poised to propel significant developments in understanding and diagnosing genetic disorders, thereby enhancing patient care. Their work ethic and enthusiasm set a remarkable example for aspiring professionals entering this critical domain.

Among the awardees, Rafael Garrett da Costa, PhD, has been acknowledged with the Clinical Biochemical Genetics Fellowship Award. As a Senior Staff Scientist at Boston Children’s Hospital and Harvard Medical School’s Department of Laboratory Medicine, Dr. Garrett da Costa’s expertise lies in mass spectrometry and metabolomics. His journey began with a BSc in Pharmacy, followed by an MSc and PhD in Chemistry from Brazil’s Federal University of Rio de Janeiro. His research primarily focuses on elucidating rare metabolic disorders and refining laboratory diagnostic methodologies. Over his extensive career, he has authored over 60 peer-reviewed articles, contributing significantly to the available literature in biochemical genetics and nurturing new talent through mentorship.

In his accolades acceptance speech, Dr. Garrett da Costa expressed profound gratitude for the fellowship, acknowledging it as a vital opportunity to broaden his competency in clinical biochemical genetics. His commitment to improving patient testing and care illustrates the fellowship’s pivotal role in transforming individual expertise into broader healthcare improvements, especially for those suffering from metabolic disorders.

The Laboratory Genetics and Genomics Fellowship Award is presented to Atlas Sardoo, PhD, a determined scientist at the National Institutes of Health (NIH). Dr. Sardoo, who holds a PhD in Human Genetics, is at the forefront of studying the connections between viral infections and liver cancer. Her research endeavors include developing predictive models to assess cancer risk in patients. Fuelled by her passion for integrating bioinformatics with clinical practices, Dr. Sardoo is poised to utilize the Laboratory Genetics and Genomics Fellowship effectively, with aspirations to apply her insights to genetic testing advancements.

Upon receiving her award, Dr. Sardoo conveyed her appreciation for the acknowledgment, viewing it as an inspiration to further her work in the intersection of clinical genetics and patient care. The importance of genomic research in understanding complex diseases underscores the significance of her contributions to future therapeutic strategies and enhances the potential for improved patient outcomes.

Recognized with the Ophthalmic Genetics Specialty Fellowship Award, Emily S. Levine, MD, MTM, is a notable figure at the Casey Eye Institute, located within Oregon Health and Science University. Dr. Levine’s academic journey led her to obtain a BA in Biology and a minor in Computer Science from Bryn Mawr College, graduating with distinguished accolades. Following her undergraduate studies, she conducted meaningful research in the field of retinal physiology before pursuing a Master’s degree in Translational Medicine. She completed her medical education at Tufts University, where she excelled and immersed herself in innovative ophthalmic research.

Dr. Levine’s commitment to enhancing care for patients with genetic eye conditions has led her to her current role as a chief ophthalmology resident, where she will begin a specialized fellowship focused on ophthalmic genetics this summer. Her heartfelt acknowledgment of receiving the Next Generation Award emphasizes her dedication to serving affected families and advancing the understanding of hereditary eye disorders. The fellowship not only celebrates her previous achievements but also recognizes her future potential in delivering superior care to patients facing genetic ophthalmic challenges.

Lastly, the Medical Biochemical Genetics Subspecialty Fellowship Award is awarded to Daniel R. Brooks, MD, a resident in the combined Pediatrics/Medical Genetics and Genomics program at Baylor College of Medicine and Texas Children’s Hospital. Dr. Brooks embodies the fusion of clinical competency and patient advocacy, elevating healthcare accessibility. His educational pathway, which includes an MD from the University of Michigan and an undergraduate degree in Biology from the University of Pennsylvania, has shaped his holistic view of genetic medicine.

His research endeavors reflect pressing issues surrounding prenatal diagnostics and the identification of rare genetic conditions, striving to expand genetic services to marginalized populations. Dr. Brooks has made noteworthy contributions to the scientific literature, with published works in respected journals such as Human Genetics and Prenatal Diagnosis. His involvement in initiatives like the NIH-funded Project GIVE sheds light on systematic healthcare disparities, providing telehealth services to underserved communities—a testament to his commitment to equitable healthcare delivery.

In his reflections on receiving the ACMGF Next Generation Fellowship award, Dr. Brooks reiterated his dedication to ensuring that genetic medicine is accessible to all individuals, irrespective of their socioeconomic background. The fellowship serves as momentum in his mission to bridge diagnostic gaps and advocate for underrepresented communities, emphasizing the importance of inclusivity in cutting-edge medical genetics.

The ACMG Foundation for Genetic and Genomic Medicine has been a pillar in advancing the field since its establishment in 1992. It operates as a 501(c)(3) nonprofit and plays a critical role in nurturing future medical geneticists and genetic counselors while promoting essential research within the field. The organization coordinates efforts to translate genetic discoveries into tangible health benefits, cultivating a community geared towards enhancing patient care through genetic literacy and genomics.

As genetic medicine continues to evolve, the commitment demonstrated by the Next Generation Fellowship awardees sets a foundation for groundbreaking developments in healthcare. The work of these young professionals not only demonstrates the immediate benefits of genomic research but also underscores the significance of continued investment in training and supporting the next generation of leaders in medical genetics. Their stories reflect vibrant aspirations to transform healthcare landscapes, ensuring that advancements in genetic insights translate to real-world applications that significantly enhance patient outcomes globally.

Ultimately, this year’s ACMG Foundation Next Generation Fellowship recipients symbolize hope and progress within the genetic and genomic medicine community. Their diverse backgrounds and research endeavors collectively contribute to the broader mission of the ACMG Foundation—to create better health through genetics, paving the way for the future of medical care and patient advocacy.

Subject of Research: The transformative role of early career professionals in medical genetics and genomics
Article Title: ACMG Foundation Recognizes Next Generation of Leaders in Genetic and Genomic Medicine
News Publication Date: N/A
Web References: https://www.acmgfoundation.org/ACMGF/Who-We-Are/Vision_and_Mission/ACMGF/Who/Vision_and_Mission.aspx?hkey=4ed44ad4-196d-4875-96e3-d10eead7b19b
References: N/A
Image Credits: N/A

Keywords: ACMG Foundation, Next Generation Fellowship, Medical Genetics, Genomics, Genetic Research, Patient Care, Fellowship Award